Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose f…

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...
Daily Jang

Canada’s measles outbreak causes Americas region to lose elimination status

Canada is no longer considered measles free as it failed to control an outbreak for 12 months. This causes the Americas region as a whole to lose its measles elimination status, even though the other ...